Australia markets open in 32 minutes

Microbix Biosystems Inc. (MBXBF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.25000.0000 (0.00%)
At close: 01:44PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.2500
Open0.2500
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.2500 - 0.2500
52-week range0.1710 - 0.3530
Volume2,000
Avg. volume5,566
Market cap34.354M
Beta (5Y monthly)0.23
PE ratio (TTM)12.50
EPS (TTM)0.0200
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Microbix Presenting at the 2024 Bloom Burton Conference

    MISSISSAUGA, Ontario, April 11, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Center, North Building, on April 16 and 17, 2024. The Conference provides an opportunity to connect with Canadian, U.S., and international investors who are in

  • GlobeNewswire

    Microbix Announces Annual and Special Meeting Voting Results

    MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company (the “Meeting”) which was held on March 27, 2024. At the Meeting, 42.64% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the Meeting. Details of all resolut

  • GlobeNewswire

    Microbix’s Clot-Buster Drug Project Advances

    Sequel Pharma Executes Agreement with CDMO for Drug Substance ProductionMISSISSAUGA, Canada, March 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the